Tyler Rehbein,Tong Tong Wu,Simona Treidler,Davide Pareyson,Richard Lewis,Sabrina W Yum,Brett A McCray,Sindhu Ramchandren,Joshua Burns,Jun Li,Richard S Finkel,Steven S Scherer,Stephan Zuchner,Michael E Shy,Mary M Reilly,David N Herrmann,Julian Blake,Kayla Cornett,Thomas O Crawford,Federica Rachele Danti,Gabrielle Donlevy,Katy Eichinger,Tim Estilow,Shawna M E Feely,Matilde Laura,Manoj Menezes,Isabella Moroni,Chiara Pisciotta,Alex Rossor,Gita Ramdharry,Paola Saveri,Giulia Schirinzi,Rosemary R Shy,Mariola Skorupinska,Janet E Sowden,Charlotte J Sumner,Dragan Vujovic,Inherited Neuropathy Consortium-Rare Diseases Clinical Research Network (INC-RDCRN)

Abstract:Recessive SH3TC2 variants cause Charcot-Marie-Tooth disease type 4C (CMT4C). CMT4C is typically a sensorimotor demyelinating polyneuropathy, marked by early onset spinal deformities, but its clinical characteristics and severity are quite variable. Clear relationships between pathogenic variants and the spectrum of disease manifestations are to date lacking. Gene replacement therapy has been shown to ameliorate the phenotype in a mouse model of CMT4C, emphasizing the need for natural history studies to inform clinical trial readiness. Data, including both genetic information and clinical characteristics, were compiled from the longitudinal, prospective dataset of the Inherited Neuropathy Consortium, a member of the Rare Diseases Clinical Research Network (INC-RDCRN). The Charcot Marie Tooth Neuropathy Score (CMTNS), Examination Score (CMTES) and the Rasch-weighted CMTES (CMTES-R) were used to describe symptoms, neurologic examinations, and neurophysiologic characteristics. Standardized response means were calculated at yearly intervals and a mixed model for repeated measures was used to estimate the change in CMTES and CMTES-R over time. 56 individuals (59% female), median age 27 years (range 2–67 years) with homozygous or compound heterozygous variants in SH3TC2 were identified, including 34 unique variants, 14 of which have not previously been published. 28 participants had longitudinal data available. While there was not a significant difference in the CMTES in those with protein-truncating versus non-protein-truncating variants, there were significant differences in the mean ulnar nerve compound muscle action potential amplitude, the mean radial sensory nerve action potential amplitude, and in the prevalence of scoliosis, suggesting the possibility of a milder phenotype in individuals with one or two non-protein-truncating variants. Overall, the mean value of the CMTES was 13, reflecting moderate clinical severity. There was a high rate of scoliosis (81%), scoliosis surgery (36%), and walking difficulty (94%) among study participants. The CMTES and CMTES-R appeared moderately responsive to change over extended follow-up, demonstrating a standardized response mean of 0.81 standard deviation units or 0.71 standard deviation units respectively, over 3 years. Our analysis represents the largest cross-sectional and only longitudinal study to date, of the clinical phenotype of both adults and children with CMT4C. With the promise of upcoming genetic treatments, this data will further define the natural history of the disease and inform study design in preparation for clinical trials.

Mild Late-Onset Sensory Neuropathy Associated with Heterozygous Missense GDAP1 Variants

[A Genotyping Study of 13 Cases of Early-Onset Charcot-Marie-Tooth Disease].

Mutation Analysis of Ganglioside-Induced Differentiation Associated Protein-1 Gene in Chinese Charcot-Marie-Tooth Disease

Genetic Spectrum of MCM3AP and Its Relationship with Phenotype of Charcot‐Marie‐Tooth Disease

[Analysis of the Pathological Features and Gene Mutations of Chinese Patients with Charcot-Marie-Tooth Disease].

Phenotype of Patients With Charcot-Marie-Tooth With the p.His123Arg Mutation in GDAP1 in Northern Finland

Clinical and Neuroimaging Features in Charcot-Marie-Tooth Patients with GDAP1 Mutations

Genotype–phenotype correlation and frequency of distribution in a cohort of Chinese Charcot–Marie–Tooth patients associated with GDAP1 mutations

Similar Clinical, Pathological, and Genetic Features in Chinese Patients with Autosomal Recessive and Dominant Charcot–Marie–Tooth Disease Type 2K

Novel compound heterozygous missense mutations in GDAP1 cause Charcot–Marie–Tooth type 4A

Autosomal dominant GDAP1 mutation with severe phenotype and respiratory involvement: A case report

The GDAP1 p.Glu222Lys Variant-Weak Pathogenic Effect, Cumulative Effect of Weak Sequence Variants, or Synergy of Both Factors?

Genetic and clinical profile of 15 Chinese families with GDAP1‐related Charcot–Marie–Tooth disease and identification of H256R as a frequent mutation

Lack of GDAP1 Induces Neuronal Calcium and Mitochondrial Defects in a Knockout Mouse Model of Charcot-Marie-Tooth Neuropathy

Neuropilin 1 sequestration by neuropathogenic mutant glycyl-tRNA synthetase is permissive to vascular homeostasis

Neuropathy due to bi-allelic SH3TC2 variants: Genotype-phenotype correlation and natural history

A Novel Missense Mutation in Peripheral Myelin Protein-22 Causes Charcot-Marie-Tooth Disease

Novel GDAP1 Mutation in a Vietnamese Family with Charcot-Marie-Tooth Disease

Identification and functional characterization of novel GDAP1 variants in Chinese patients with Charcot–Marie–Tooth disease

Recent Advances in the Genetics of Hereditary Axonal Sensory-Motor Neuropathies Type 2

EGR2-related Mixed Demyelinating and Axonal Charcot-Marie-Tooth Disease: an Electrodiagnostic, Nerve Imaging, and Histological Study.